BioAtla, Inc. (BCAB)
NASDAQ: BCAB · IEX Real-Time Price · USD
1.680
-0.100 (-5.62%)
Jul 22, 2024, 9:30 AM EDT - Market open
BioAtla Employees
BioAtla had 65 employees as of December 31, 2023. The number of employees decreased by 1 or -1.52% compared to the previous year.
Employees
65
Change (1Y)
-1
Growth (1Y)
-1.52%
Revenue / Employee
n/a
Profits / Employee
-$1,834,400
Market Cap
81.80M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 65 | -1 | -1.52% |
Dec 31, 2022 | 66 | 10 | 17.86% |
Dec 31, 2021 | 56 | 20 | 55.56% |
Dec 31, 2020 | 36 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Sangamo Therapeutics | 405 |
Protalix BioTherapeutics | 208 |
DBV Technologies | 105 |
Verastem | 73 |
Chimerix | 72 |
AN2 Therapeutics | 41 |
SCYNEXIS | 29 |
Genenta Science | 14 |
BCAB News
- 7 weeks ago - BioAtla to Participate in the Jefferies Global Healthcare Conference - GlobeNewsWire
- 2 months ago - BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewsWire
- 2 months ago - BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress - GlobeNewsWire
- 2 months ago - BioAtla to Participate in the Citizens JMP Life Sciences Conference - GlobeNewsWire
- 2 months ago - BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024 - GlobeNewsWire
- 2 months ago - BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors - GlobeNewsWire
- 3 months ago - BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewsWire
- 4 months ago - BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress - GlobeNewsWire